DFTX
$42.63
$-1.20 (-2.73%)-2.73%
ClosedLoading chart...
IndexN/A
Market Cap5.66B
Enterprise Value0.94B
IncomeN/A
SalesN/A
EmployeesN/A
P/EN/A
P/S0.00
P/B3.60
P/C-9.09
EV/EBITDA-5.26
EV/SalesN/A
EPS (ttm)N/A
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume1.70M
Shs OutstandN/A
Change-2.89%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Financial statements for DFTX are not yet available.
Company coverage
Latest news
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Discover more
You may be interested in